Eli Lilly’s Sales Slash… And How To Position ...

Stocks sell off to wrap out a second straight week of losses, with the Nasdaq entering into correction territory. The latest developments out of the Middle East weighing on markets, and if there’s more pain to come next week. Plus it’s not just equities feeling the impact, as oil ...  Show more

Rates across the world are climbing as central banks raise inflation warnings. How yesterday’s Fed decision sets up a potential rate *hike* at the bank’s June meeting, and when the recent jump in yields could finally hit the equity market. Plus, Eli Lilly’s latest trial data, Nov ...  Show more

It’s been a year since Silicon Valley Bank’s collapse left everyone worried that the US’s banking sector sat on shaky ground. Despite that turmoil, one bank stands out: JPMorgan Chase. The largest bank in the country, JPMorgan took home record profits in 2023, and its dom ...

David Faber and Jim Cramer began the hour by breaking down another volatile day for the markets, with the major indices coming off their 4th negative session in 5. JPMorgan also raised their odds of a U.S. recession by year end to 35%. A big earnings mover today included Eli L ...

Chris Whalen, chairman of Whalen Global Advisors, returns to Forward Guidance to comment on the ample and growing earnings of the big banks (particularly JPMorgan Chase, whose stock surged over 7% on rosy net income and increasing deposits).  Whalen argues that banks’ unrealized ...  Show more

David Kostin, Goldman Sachs chief US equity strategist, says the group of Magnificent Seven stocks are now the Maleficent Seven and they've been a "real source of pain" in the market this year. Kostin lowered his 2025 year-end S&P 500 price target from 6,500 to 6,200. Kostin spea ...  Show more